- The Government of Spain is providing 24.3 million euros through the Ministry of Science, Innovation and Universities, reinforcing its commitment to technological innovation for health.
- Kutxa Fundazioa leads the Basque investment with 15 million euros, along with the contribution of 10.5 million from the Basque Government and Ekarpen and 2 million from BBK, completing a Basque institutional commitment of 27.5 million euros.
- The operation will allow strengthening the development of new oncological therapies and advancing the implementation of a Fill & Finish manufacturing plant specializing in high-potency drugs.
The Basque biotech company ONCOMATRYX BIOPHARMA, S.A. has successfully completed a capital increase amounting to approximately of 58 million euros with the ultimate goal of evolving from a biotech company into an integrated biopharmaceutical company, strengthening both its clinical development and its industrial capabilities.
The operation is backed by the Ministry of Science, Innovation and Universities through the public venture capital company Innvierte and Kutxa Fundazioa, the Basque Government, Ekarpen, BBK and other historical private investors from the company, both national and international.
Among the strategic initiatives contemplated is the development of a Fill & Finish manufacturing plant specializing in high-potency oncology drugs in Gipuzkoa, an infrastructure that will contribute to strengthening European industrial capacity in the manufacture of advanced biological medicines and strengthening the technological autonomy of the pharmaceutical sector.
The Ministry of Science, Innovation and Universities, through the public venture capital company INNVIERTE of the CDTI, the State Agency for Innovation, will contribute 24.3 million from its line of co-investments in strategic companies. This operation is part of the commitment of the Spanish government to specifically promote the field of technological innovation for health, whose impact will bring added value and improve the quality of life of citizens.
For its part, Kutxa Fundazioa will allocate 15 million euros of the total amount round of 58 million euros launched by Oncomatryx, significantly increasing its presence in the company’s shareholders, going from a 1.7% to 7.4%. With this decision, the entity reaffirms its strategic mission of contributing to social well-being through the promotion of business development and industrial impact in Gipuzkoa.
«This investment fully responds to our objectives of fostering innovation and competitiveness, consolidating our commitment to transformative projects that generate a real impact in our ecosystem.»This is a very important step," points out Eluska Sukia, Director of Investments at Kutxa Fundazioa.
The Basque Government, in collaboration with Ekarpen, will contribute 10.4 million euros in this new funding round, which, in the words of the Minister of Industry, Energy Transition and Sustainability, Mikel Jauregi, “This operation will allow maintaining the shareholding in the company at 17.96%. With this operation, the institutions reinforce our commitment to the development of a highly specialized biotechnology sector, considered strategic for the competitiveness and diversification of the Basque industrial fabric.”.
In addition, he has stated “This investment contributes to consolidating an innovation hub in Gipuzkoa in the field of life sciences and advanced technologies, boosting scientific and technological capabilities with high added value and promoting new skilled employment that our daughters and sons aspire to.”.
The Minister of Science, Innovation and Universities, Diana Morant, He has assured that “This operation is an example of the public-private partnership model promoted by the Spanish Government to strengthen our science and innovation system. Investing in Oncomatryx means investing in more advanced oncological therapies, in industrial capacity in biomedicine, and in positioning our country at the forefront of biotechnology for the benefit of health and the quality of life of citizens.”.
Scientific, economic and social impact
To Laureano Simón, Founder of Oncomatryx, “This capital expansion is much more than a financial transaction. It is confirmation that Oncomatryx is ready to make the leap from a research company to an integrated biopharmaceutical company. The support of institutional and private investors who have been investing in this project for years allows us to advance in the construction of our own industrial infrastructure that will strengthen Europe’s capacity to manufacture the future oncology drugs.”
Oncomatryx approaches cancer from a perspective different from traditional ones, targeting the tumor microenvironment, a key element in tumor growth and resistance. This pioneering approach opens new therapeutic avenues to improve the effectiveness of treatments.
In fact, their drug called OMTX705 is currently in Phase 1B-2A clinical trial with people, after completing a first phase where 100 patients have been treated in reference hospitals in Spain and the United States, with promising results and high expectations both in the clinical and scientific fields.
Oncomatryx maintains international license agreements with Asian biotechnology companies that globally validate its technological platform, and has been recognized by the European Union as a strategic project through the EIC Accelerator program, which has supported its development with 12.5 million euros.
This scientific position places Oncomatryx in a unique position within the development of new oncological therapies.
The investment will also position Euskadi as a relevant hub in the field of advanced oncology therapies, generating skilled employment and attracting high-value-added industrial activity.